Lead Generation

Our Lead Generation Services:

Primary Screen

Leveraging  CETSA® for primary screening ensures that only compounds demonstrating genuine cellular target engagement move forward. This significantly increases the chances of identifying high-quality drug candidates, minimizes false positives, and accelerates discovery. 

Key Benefits 

Accelerated Discovery – Speed up your drug discovery process with efficient, high-throughput screening. y your treatment 

True Target Engagement – Identify compounds with verified cellular target interaction. 

Fewer False Positives – Eliminate non-specific hits early to streamline follow-up efforts. 

Hit Confirmation

At Pelago Bioscience, we offer comprehensive confirmatory testing and in-depth compound evaluation. Our approach helps refine the compound design and prioritize the strongest candidates, streamlining your hit confirmation process and accelerating the path to lead optimization. 

Key Benefits 

Streamlined Development Path – Accelerate progression to lead optimization by eliminating weak candidates early roven success developing assays for both well-established and hard-to-drug targets 

Physiologically Relevant Validation – Confirm target engagement in living cells for more predictive results 

Improved Hit Prioritization – More confidently Focus resources on the most promising chemical series 

Potency Ranking 

Potency ranking is essential in the lead optimization phase of drug discovery for selecting and refining compounds with strong target engagement

CETSA measures how well a compound binds to its target in intact, biologically relevant cells, ensuring relevance to disease models. This helps establish a clear link between cellular target engagement and functional readouts, helping to establish a clear Structure-Activity Relationship (SAR) and ensuring that potency improvements translate into biological effects

Key Benefits 

  • Biologically Relevant Potency Data – Measure target engagement in intact cells, ensuring potency rankings reflect real-world disease models. 
  • Stronger SAR Development – Establish a clear relationship between compound binding and functional biological effects. 
  • Reduced Late-Stage Attrition – Prioritize compounds with verified cellular target engagement to lower the risk of failures in later development stages. 

Functional Assays

By combining cutting-edge technologies with expert assay development, we help demonstrate that compound binding translates into a measurable functional response—enabling more informed, data-driven decision-making throughout your drug discovery and development process. 

Key Benefits 

Informed Decision-Making – Strengthen confidence in target validation and guide compound optimization with actionable data. 

Validated Biological Relevance – Establish a link between target engagement and functional cellular response. 

Comprehensive Assay Solutions – Access both CETSA and traditional assays to assess target interaction and downstream effects. 

Selectivity Profiling

Selectivity Profiling allows researchers to assess compound binding across individual proteins and entire biological pathways, offering insights beyond the limitations of conventional target panels. Given that many drug candidates interact with multiple physiological targets, our approach helps reveal off-target effects that traditional screening methods often miss. 

Key Benefits 

Flexible Service Options – Choose between fully customized profiling or a faster, standardized service in lysate. 

Comprehensive Off-Target Detection – Unbiased, proteome-wide profiling reveals off-target interactions missed by conventional panels. 

Enhanced Drug Safety and Efficacy – Ensure selective binding to the correct targets, minimizing potential liabilities early in development. 

"Pelago Bioscience offers exceptional technical expertise in all aspects of target deconvolution using CETSA – including study design, sample preparation, LC-MS data acquisition, and statistical processing. Our collaboration always proceeded effectively due to Pelago Bioscience's responsiveness, scientific commitment, and dedication to clients resulting in delivery of impactful scientific results."

Benjamin Fontaine, Senior Scientist

LifeMine Therapeutics

"Using our world leading expertise in CETSA we have created a faster and more efficient drug discovery process. We take great pride in knowing our customers are bringing new medicines to market more quickly thanks to our help."

Michael Dabrowski, CEO and Co-founder

Pelago Bioscience

"Chemoproteomics is like taking a watch to pieces and counting the cogs – it doesn't tell you which cogs drive which process and how the wider system works. This is why using CETSA can add so much value to your target identification studies."

Pär Nordlund, Professor and Inventor of CETSA

Karolinska Institute

"Our small molecule drug discovery project was seeking a robust assay allowing to screen against the target of interest expressed in its natural cellular environment. Pelago Bioscience's expertise in drug discovery projects, specifically in the CETSA platform and high throughput screens was the key to achieving our goals. We found Pelago's team to be professional, knowledgeable, flexible and dedicated. We highly recommend Pelago Bioscience for drug discovery projects."

Po-Shun Lee, Chief Medical Officer

Generian

"CETSA data is a keystone in our SAR analysis, and by assessing cellular target engagement of our compounds across multiple cell lines we gain confidence in our project prioritizations."

Peter Joyce, CEO and Co-Founder

Grey Wolf Therapeutics

“As we approached late preclinical development, our lead compound demonstrated strong efficacy and a favorable toxicity profile.Partnering with Pelago Bioscience, we leveraged their expertise in CETSA technology to successfully identify and validate the protein target. With the comprehensive data package they provided, we met investor requirements and gained the support needed to move forward. The Pelago team´s swift and precise response was invaluable throughout the process, and their scientific excellence made a real difference. We’re highly encouraged by the results and grateful for their outstanding collaboration.”

Martin Bonde, CEO

Inthera Bioscience AG

"While ligand binding assays are commonly used for PK/PD studies in clinical trials of biologics and endogenous protein quantification, Lipum AB sought to establish an orthogonal quantitative LC-MS/MS method for our target protein, bile salt-stimulated lipase (BSSL). We chose Pelago Bioscience as our partner due to their rapid project initiation, collaborative approach, and extensive expertise in processing complex biological samples using high-resolution mass spectrometry. Working with one of the best proteomics labs in the Nordics, Pelago's team delivered high-quality results that aligned perfectly with our clinical research goals."

Ola Sandborgh, CEO

Lipum AB